Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
See Latest ArticlesComparison of thiomersal-free and thiomersal-containing formulations of a recombinant hepatitis B vaccine (Hepavax-Gene) in healthy adults
Vaccine , 08/23/06
I. Rebedea, et al. - Hepavax-Gene TF was non-inferior to Hepavax-Gene and Engerix-B with respect to seroprotection rates (>=10 IU/L) 1 month after the third vaccination using the 0–1–6 month schedule, with 99.1% for both Hepavax-Gene formulations and 100% for Engerix-B of subjects' seroprotected in each group. The seroprotection rate after the 0–1–2 schedule was 89.6% for Hepavax-Gene TF, lower than for Hepavax-Gene (94.2%) but comparable to Engerix-B (86.4%). Furthermore, Hepavax-Gene TF was as well tolerated as the comparator vaccines
Related Articles
A significant reduction in hepatitis B virus infection among the children of Shandong Province, China: the effect of 15 years of universal infant hepatitis B vaccination
International Journal of Infectious Diseases, 12/04/09
Relevance Score: 84%%
Lichen planus in childhood: report of 100 cases
Clinical and Experimental Dermatology, 11/10/09
Relevance Score: 82%%
Hepatitis B vaccinations among Koreans: Results from 2005 Korea National Cancer Screening Survey
BMC Infectious Diseases, 11/25/09
Relevance Score: 81%%
Molecular Sequence Data of Hepatitis B Virus and Genetic Diversity After Vaccination
American Journal of Epidemiology, 11/13/09
Relevance Score: 81%%
How long does hepatitis B vaccine protection last?
Reuters, 11/03/09
Relevance Score: 81%%
Today in Vaccine/Immunotherapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Response to a Monovalent 2009 Influenza A (H1N1) Vaccine
New England Journal of Medicine, 12/17/09
A Novel Influenza A (H1N1) Vaccine in Various Age Groups
New England Journal of Medicine, 12/17/09
Efficacy and Safety of Pentavalent Human-Bovine Reassortant Rotavirus Vaccine When Administered With Greater Than 10 Weeks Between Doses
The Pediatric Infectious Disease Journal, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor